Global Contrast Enhanced Ultrasound Market Driven by Demand for Early Detection of Chronic Diseases
Posted on 22 Aug 2023
Contrast-Enhanced Ultrasound (CEUS) is a non-ionizing imaging method that differs from CT scans and X-rays in its non-utilization of ionizing radiation. This inherent feature results in minimal patient risk, rendering it a safer alternative, particularly for vulnerable groups such as pregnant women, children, and those with delicate health conditions. CEUS employs contrast agents to enhance the visualization of blood flow and perfusion within bodily organs and tissues. This heightened precision in imaging soft tissues renders CEUS especially valuable for the assessment of vascular irregularities, detection of minute lesions, and characterization of tumors. CEUS stands out for its ability to provide real-time, dynamic imagery of blood circulation and tissue perfusion. This capability empowers medical professionals to immediately and interactively evaluate organ function and pathological conditions. The real-time feature proves particularly advantageous during interventional procedures, enabling physicians to accurately target and administer treatment at the moment. In comparison to imaging modalities like MRI and CT, CEUS boasts a generally more cost-effective profile, making it a viable option for healthcare systems aiming to optimize resources without compromising diagnostic precision.
The global CEUS market is projected to grow at a CAGR of 6.1% from an estimated USD 1.6 billion in 2023 to USD 2.1 billion by 2028, driven by the rising prevalence of chronic diseases and technological developments. Amidst the evolution in medical imaging technology, CEUS emerges as a safer, more accessible, and budget-friendly substitute for conventional imaging methods like CT scans and MRI. With its non-invasive characteristics and real-time imaging capacity, CEUS is bound to find increased adoption across various applications, encompassing liver and kidney imaging, vascular assessment, and the identification and characterization of tumors. Notably, the CEUS market is poised for rapid developments in contrast agents, which will improve image quality and diagnostic accuracy. Additionally, advancements in AI-powered image analysis are set to improve the interpretation and diagnosis of CEUS studies, granting healthcare practitioners the ability to make prompt and well-informed clinical judgments. Given the vast research and clinical evidence supporting the beneficial use of CEUS, regulatory authorities are likely to expand its approved applications, thereby driving greater acceptance and integration into routine medical practices. This growth in the CEUS market will ultimately translate into enhanced patient outcomes, more effective disease management, and a more patient-centric approach to medical imaging in the near future.
These are the latest findings of MarketsandMarkets (Northbrook, IL, USA), a market research firm.
Based on product, the equipment segment accounted for the highest share of the CEUS market in 2022 while the contrast agents segment is expected to register the highest CAGR over the forecast period. On the basis of application, the diagnostic applications segment accounted for the largest share of the CEUS market in 2022, while the therapeutic applications segment is expected to register the highest CAGR during the forecast period. Factors such as the introduction of novel software and the rising adoption of high-end instruments in end-user facilities will drive the growth of the therapeutic applications segment. Based on end-user, the hospital and surgical centers segment accounted for the largest share of the CEUS market in 2022, driven by the increasing geriatric population and rise in the number of hospitals. Geographically, the Asia Pacific CEUS market is anticipated to register the highest CAGR during the forecast period, driven by the expansion of manufacturing capabilities and the rise in the adoption of high-end equipment in the APAC region.
Related Links:
MarketsandMarkets
.jpg)
.jpeg)
